AnaptysBio, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 42.21 million compared to USD 26.41 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 0.93 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.85 USD | -0.83% |
|
+4.19% | +11.34% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.34% | 657M | |
+16.45% | 123B | |
+21.96% | 115B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023